| In-patient management and treatment satisfaction after intravitreous plasminogen activator injection. | |
| | |
MedLine Citation:
|
PMID: 16596407 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To assess patient satisfaction after intravitreous plasminogen activator injections for subretinal hemorrhages secondary to age-related macular degeneration (AMD) and to analyse how it relates to the patients' postoperative visual and functional abilities. Further, to suggest ways to improve in-patient management and thereby treatment satisfaction. METHODS: A consecutive series of 101 patients with a subretinal hemorrhage of at least one disk diameter were enrolled in this longitudinal prospective study conducted during 2001-2004. After complete preoperative eye examination all patients were treated with intravitreal injection of 25 microg recombinant tissue plasminogen activator (rTPA) and 0.5 ml sulphur hexafluoride gas (SF6), followed by face-down positioning for 1 week. Patient satisfaction was assessed using standardised questionnaires administered postoperatively at 4 and 12 months. Outcome measures were: (1) responses to the patient satisfaction survey, (2) degree of satisfaction with in-patient management, (3) subjective change in the patients' functional status, and (4) visual acuity results. RESULTS: Whereas the patients' actual functional status deteriorated from a median value of 2.4 at 4 months to 3.4 at 12 months, their recall of their preoperative functional status shifted from a median value of 4.2 to to 2.3, consecutively. Twelve months after treatment, 75% of patients reported an improved visual acuity, however, only 12% reported satisfaction with treatment. 67.4-87% of patients were dissatisfied with various areas of in-patient management. CONCLUSIONS: Satisfaction with plasminogen activator injection treatment is low even though patients experience an improved visual and functional status at 12 months. This suggests that the current system requires improvement in certain areas such as in-patient management. |
| | |
Authors:
|
Maneli Mozaffarieh; Harald Heinzl; Stefan Sacu; Andreas Wedrich |
Related Documents
:
|
17467527 - Optical coherence tomographic pattern may predict visual outcome after intravitreal tri... 17908257 - Resolution of macular oedema in occult choroidal neovascularization under oral sorafeni... 16898387 - Photodynamic therapy for choroidal neovascularization associated with submacular hemorr... 14676697 - Outcome for traumatic optic neuropathy--surgical versus nonsurgical treatment. 18785847 - Effect of low-level laser therapy on mast cells in viability of the transverse rectus a... 21737787 - Intramyocardial, autologous cd34+ cell therapy for refractory angina. |
Publication Detail:
|
Type: Journal Article Date: 2006-04-05 |
Journal Detail:
|
Title: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie Volume: 244 ISSN: 0721-832X ISO Abbreviation: Graefes Arch. Clin. Exp. Ophthalmol. Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-11-09 Completed Date: 2007-08-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8205248 Medline TA: Graefes Arch Clin Exp Ophthalmol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1421-8 Citation Subset: IM |
Affiliation:
|
Department of Ophthalmology, Medical University of Vienna, Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Drug Therapy, Combination Fibrinolytic Agents / administration & dosage* Follow-Up Studies Humans Injections Inpatients Macular Degeneration / complications Patient Satisfaction* Prone Position Prospective Studies Questionnaires Recombinant Proteins / administration & dosage Retinal Hemorrhage / drug therapy*, etiology, psychology* Sulfur Hexafluoride / administration & dosage* Tissue Plasminogen Activator / administration & dosage* Visual Acuity / physiology Vitreous Body |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Recombinant Proteins; 2551-62-4/Sulfur Hexafluoride; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outflow mechanisms after deep sclerectomy with two different designs of collagen implant in an anima...
Next Document: A novel method for patch-clamp automation.